Changzhou BeamCyte Biotechnology Co., Ltd. was established in December 2013 and is located in Haibo Medical Device Technology Park, High-tech Development Zone, Xinbei District, Changzhou City. It is a high-tech specialized company integrating independent research and development, production, and sales. The company currently has more than 20 R&D and application personnel holding doctoral and master's degrees, and possesses high-level optics laboratories, comprehensive electrical laboratories, mechanical structure laboratories, as well as advanced production plants and production lines. It also maintains close project cooperation with a R&D team in Silicon Valley, California, USA. The company's flagship product is the flow cytometer, focusing on the research and development of precise cell quantification detection and analysis technology, committed to forming a series of products for different industries, different scales, and different applications such as scientific research, experiments, and clinical applications. Since its establishment, the company has strengthened its overall operations by implementing the quality management system and management model of GB/T 19001 (idt ISO 9001) and YY/T 0287 (idt ISO 13485) standards, enhancing the quality awareness of all employees, in order to continuously develop better and more applicable products to meet the development needs of China's medical and health undertakings.
Company Purpose: Customer-oriented, persisting in innovation, providing precise and reliable products and services.
Products achieved: The BeamCyte series flow cytometers, developed and designed by the team through 3 years of product and process iterative R&D and design, over 1 year of client-side verification and feedback optimization, with multi-point coverage achieving micro-innovation and continuous improvement, have achieved product technology breakthroughs from hardware to software systems and a highly reliable mass production rate guarantee. The products have outstanding market competitiveness and technological leadership advantages, and entered the market at the end of 2017.
The BeamCyte flow cytometer not only broke the long-term monopoly of foreign flow cytometry technology products, but also achieved a product volume of less than 1/4 of mainstream imported instruments. Its technical indicators surpass those of imported medium-to-large machines, and the breakthrough technologies and processes applied have controlled costs to less than 1/5 of imported instruments. BeamCyte Biotechnology has become one of the few domestic manufacturers of flow immunofluorescence technology, and its products have outstanding market competitive advantages and technological leadership advantages.
The energetic BeamCyte team, persisting in innovation and continuous improvement, is waiting for you to join!
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows